…new grants for clinical trial research, including a grant for ustekinumab (STELARA®) for the prevention of graft versus host disease. STELARA®, marketed by Janssen Biotech, is currently approved for the…
…new grants for clinical trial research, including a grant for ustekinumab (STELARA®) for the prevention of graft versus host disease. STELARA®, marketed by Janssen Biotech, is currently approved for the…
…of 2025. Celltrion also announced last week that Celltrion Healthcare Co. (Celltrion’s marketing and distribution arm) has signed an agreement with Intract Pharma to develop the first tablet product of…
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s…
Celltrion recently announced that its trastuzumab biosimilar, Herzuma, has met the World Health Organization’s (WHO) prequalification standards. WHO prequalification status is based on an assessment of the quality, safety, and…
…BAT2506 is a biosimilar of Janssen’s SIMPONI, which is indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. According to their announcement, Bio-Thera intends…
…result of joint partnership between Teva and Celltrion to commercialize TRUXIMA® in the U.S. and Canada. Teva and Celltrion settled their BPCIA litigation against Genentech shortly before the November 2019…
…inter partes review (IPR) proceedings. Genentech v. Iancu (USPTO), Nos. 19-1263, -1265, -1267, -1270 On March 26, 2020, the Federal Circuit affirmed the PTAB’s final written decisions in IPR2017-00731, -00737,…
…a victory over Janssen regarding one of two asserted patent in U.S. district court, Celltrion and Hospira revealed in appellate court papers that they had launched their biosimilar of REMICADE…
Teva and Celltrion announced yesterday that their HERZUMA (trastuzumab-pkrb) for Injection, a biosimilar to HERCEPTIN, was available in the U.S. The biosimilar has the same indications as the reference product,…
The Korean Herald reported today that Celltrion has applied for the European Medicine Agency’s approval of CT-P17, a Humira (adaliumumab) biosimilar. According to the Korean Herald, Celltrion “expects to introduce…